Publicacions - IR Sant Pau

Cercar

13/12/2022 Mutation update for the ACTN2 gene

Ranta-aho, J, Olive, M, Vandroux, M, Roticiani, G, Dominguez, C, Johari, M, Torella, A, Bohm, J, Turon, J, Nigro, V, Hackman, P, Laporte, J, Udd, B, Savarese, M. Mutation update for the ACTN2 gene. HUMAN MUTATION. 2022; 43(12)DOI:10.1002/humu.24470. PMID:36116040. IF:3.900(Q2/3D).

01/12/2022 Water T2 could predict functional decline in patients with dysferlinopathy

Moore, U, Araujo, ECD, Reyngoudt, H, Gordish-Dressman, H, Smith, FE, Wilson, I, James, M, Mayhew, A, Rufibach, L, Day, JW, Jones, KJ, Bharucha-Goebel, DX, Salort-Campana, E, Pestronk, A, Walter, MC, Paradas, C, Stojkovic, T, Mori-Yoshimura, M, Bravver, E, Pegoraro, E, Mendell, JR, Bushby, K, Blamire, AM, Straub, V, Carlier, PG, Diaz-Manera, J. Water T2 could predict functional decline in patients with dysferlinopathy. Journal of Cachexia Sarcopenia and Muscle. 2022; 13(6)DOI:10.1002/jcsm.13063. PMID:36058852. IF:8.900(Q1/1D).

01/11/2022 Dystrophinopathy Phenotypes and Modifying Factors in DMD Exon 45-55 Deletion

Poyatos-Garcia, J, Marti, P, Liquori, A, Muelas, N, Pitarch, I, Martinez-Dolz, L, Rodriguez, B, Gonzalez-Quereda, L, Damia, M, Aller, E, Selva-Gimenez, M, Vilchez, R, Diaz-Manera, J, Alonso-Perez, J, Barcena, JE, Jauregui, A, Gamez, J, Aladren, JA, Fernandez, A, Montolio, M, Azorin, I, Hervas, D, Casasus, A, Nieto, M, Gallano, P, Sevilla, T, Vilchez, JJ. Dystrophinopathy Phenotypes and Modifying Factors in DMD Exon 45-55 Deletion. ANNALS OF NEUROLOGY. 2022; 92(5)DOI:10.1002/ana.26461. PMID:35897138. IF:11.200(Q1/1D).

11/10/2022 Muscle MRI in McArdle Disease A European Multicenter Observational Study

Lokken, N, Revsbech, KL, Jacobsen, LN, Martinuzzi, A, Martin, MA, Diaz-Manera, J, Dominguez-Gonzalez, C, Brondani, G, Musumeci, O, Granata, F, Stefan, C, Merino-Sanchez, C, Peralta, CN, Khawajazada, T, Alonso-Perez, J, Toscano, A, Vissing, J. Muscle MRI in McArdle Disease A European Multicenter Observational Study. NEUROLOGY. 2022; 99(15)DOI:10.1212/WNL.0000000000200914. PMID:35853747. IF:9.900(Q1/1D).

01/10/2022 Genotype-phenotype correlations in valosin-containing protein disease: a retrospective muticentre study

Schiava, M, Ikenaga, C, Villar-Quiles, RN, Caballero-Avila, M, Topf, A, Nishino, I, Kimonis, V, Udd, B, Schoser, B, Zanoteli, E, Souza, PVS, Tasca, G, Lloyd, T, Lopez-de Munain, A, Paradas, C, Pegoraro, E, Nadaj-Pakleza, A, De Bleecker, J, Badrising, U, Alonso-Jimenez, A, Kostera-Pruszczyk, A, Miralles, F, Shin, JH, Bevilacqua, JA, Olive, M, Vorgerd, M, Kley, R, Brady, S, Williams, T, Dominguez-Gonzalez, C, Papadimas, GK, Warman, J, Claeys, KG, de Visser, M, Muelas, N, LaForet, P, Malfatti, E, Alfano, LN, Nair, SS, Manousakis, G, Kushlaf, HA, Harms, MB, Nance, C, Ramos-Fransi, A, Rodolico, C, Hewamadduma, C, Cetin, H, Garcia-Garcia, J, Pal, E, Farrugia, ME, Lamont, PJ, Quinn, C, Nedkova-Hristova, V, Peric, S, Luo, SS, Oldfors, A, Taylor, K, Ralston, S, Stojkovic, T, Weihl, C, Diaz-Manera, J. Genotype-phenotype correlations in valosin-containing protein disease: a retrospective muticentre study. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2022; 93(10)DOI:10.1136/jnnp-2022-328921. PMID:35896379. IF:11.000(Q1/1D).

01/10/2022 Autoimmune nodopathies, an emerging diagnostic category

Martin-Aguilar, L, Lleixa, C, Pascual-Goni, E. Autoimmune nodopathies, an emerging diagnostic category. CURRENT OPINION IN NEUROLOGY. 2022; 35(5)DOI:10.1097/WCO.0000000000001107. PMID:35989582. IF:4.800(Q1/3D).

20/09/2022 An International Perspective on Preceding Infections in Guillain-Barre Syndrome The IGOS-1000 Cohort

Leonhard, SE, van der Eijk, AA, Andersen, H, Antonini, G, Arends, S, Attarian, S, Barroso, FA, Bateman, KJ, Batstra, MR, Benedetti, L, van den Berg, B, Van den Bergh, P, Burmann, J, Busby, M, Casasnovas, C, Cornblath, DR, Davidson, A, Doets, AY, van Doorn, PA, de la Cour, CD, Feasby, TE, Fehmi, J, Garcia-Sobrino, T, Goldstein, JM, Gorson, KC, Granit, V, Hadden, RDM, Harbo, T, Hartung, HP, Hasan, I, Holbech, JV, Holt, JKL, Jahan, I, Islam, Z, Karafiath, S, Katzberg, HD, Kleyweg, RP, Kolb, N, Kuitwaard, K, Kuwahara, M, Kusunoki, S, Luijten, LWG, Kuwabara, S, Pan, EL, Lehmann, HC, Maas, M, Martin-Aguilar, L, Al Miller, J, Mohammad, QD, Monges, S, Nedkova-Hristova, V, Nobile-Orazio, E, Pardo, J, Pereon, Y, Querol, L, Reisin, R, Van Rijs, W, Rinaldi, S, Roberts, RC, Roodbol, J, Shahrizaila, N, Sindrup, SH, Stein, B, Cheng-Yin, T, Tankisi, H, Tio-Gillen, AP, Tous, MJS, Verboon, C, Vermeij, FH, Visser, LH, Huizinga, R, Willison, HJ, Jacobs, BC. An International Perspective on Preceding Infections in Guillain-Barre Syndrome The IGOS-1000 Cohort. NEUROLOGY. 2022; 99(12)DOI:10.1212/WNL.0000000000200885. PMID:35981895. IF:9.900(Q1/1D).

01/09/2022 Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients' Perspective: An Observational Cross-Sectional Study

Meca-Lallana, JE, Gomez-Ballesteros, R, Perez-Miralles, F, Forero, L, Sepulveda, M, Calles, C, Martinez-Gines, ML, Gonzalez-Suarez, I, Boyero, S, Romero-Pinel, L, Sempere, AP, Meca-Lallana, V, Querol, L, Costa-Frossard, L, Prefasi, D, Maurino, J. Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients' Perspective: An Observational Cross-Sectional Study. Neurology and Therapy. 2022; 11(3)DOI:10.1007/s40120-022-00356-6. PMID:35524037. IF:3.700(Q2/4D).

01/09/2022 IgG4 Valency Modulates the Pathogenicity of Anti-Neurofascin-155 IgG4 in Autoimmune Nodopathy

Jentzer, A, Attal, A, Roue, C, Raymond, J, Lleixa, C, Illa, I, Querol, L, Taieb, G, Devaux, J. IgG4 Valency Modulates the Pathogenicity of Anti-Neurofascin-155 IgG4 in Autoimmune Nodopathy. Neurology-Neuroimmunology & Neuroinflammation. 2022; 9(5)DOI:10.1212/NXI.0000000000200014. PMID:35948442. IF:8.800(Q1/1D).

01/09/2022 Gadolinium-enhanced brain lesions in multiple sclerosis relapse

Martin-Aguilar, L, Presas-Rodriguez, S, Rovira, A, Capellades, J, Massuet-Vilamajo, A, Ramio-Torrenta, L, Tintore, M, Brieva-Ruiz, L, Moral, E, Cano-Orgaz, A, Blanco, Y, Batlle-Nadal, J, Carmona, O, Gea, M, Hervas-Garcia, JV, Ramo-Tello, C. Gadolinium-enhanced brain lesions in multiple sclerosis relapse. NEUROLOGIA. 2022; 37(7)DOI:10.1016/j.nrl.2021.10.005. PMID:36064284. IF:3.900(Q2/4D).

16/08/2022 The Location of Disease-Causing DES Variants Determines the Severity of Phenotype and the Morphology of Sarcoplasmic Aggregates

Silva, AMS, Rodrigo, P, Moreno, CAM, Mendonca, RD, Estephan, ED, Camelo, CG, Campos, ED, Dias, AT, Nascimento, AM, Kulikowski, LD, Oliveira, ASB, Reed, UC, Goldfarb, LG, Olive, M, Zanoteli, E. The Location of Disease-Causing DES Variants Determines the Severity of Phenotype and the Morphology of Sarcoplasmic Aggregates. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY. 2022; 81(9)DOI:10.1093/jnen/nlac063. PMID:35898174. IF:3.200(Q2/5D).

01/07/2022 Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy

Statland, JM, Campbell, C, Desai, U, Karam, C, Diaz-Manera, J, Guptill, JT, Korngut, L, Genge, A, Tawil, RN, Elman, L, Joyce, NC, Wagner, KR, Manousakis, G, Amato, AA, Butterfield, RJ, Shieh, PB, Wicklund, M, Gamez, J, Bodkin, C, Pestronk, A, Weihl, CC, Vilchez-Padilla, JJ, Johnson, NE, Mathews, KD, Miller, B, Leneus, A, Fowler, M, van de Rijn, M, Attie, KM. Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy. MUSCLE & NERVE. 2022; 66(1)DOI:10.1002/mus.27558. PMID:35428982. IF:3.400(Q2/5D).

01/07/2022 Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis

Reyes-Leiva, D, Lopez-Contreras, J, Moga, E, Pla-Junca, F, Lynton-Pons, E, Rojas-Garcia, R, Turon-Sans, J, Querol, L, Olive, M, Alvarez-Velasco, R, Caballero-Avila, M, Carbayo, A, Vesperinas-Castro, A, Domingo, P, Illa, I, Gallardo, E, Cortes-Vicente, E. Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis. Neurology-Neuroimmunology & Neuroinflammation. 2022; 9(4)DOI:10.1212/NXI.0000000000200002. PMID:35728947. IF:8.800(Q1/1D).

01/06/2022 Three-year quantitative magnetic resonance imaging and phosphorus magnetic resonance spectroscopy study in lower limb muscle in dysferlinopathy

Reyngoudt, H, Smith, FE, Araujo, ECD, Wilson, I, Fernandez-Torron, R, James, MK, Moore, UR, Diaz-Manera, J, Marty, B, Azzabou, N, Gordish, H, Rufibach, L, Hodgson, T, Wallace, D, Ward, L, Boisserie, JM, Le Louer, J, Hilsden, H, Sutherland, H, Canal, A, Hogrel, JY, Jacobs, M, Stojkovic, T, Bushby, K, Mayhew, A, Straub, V, Carlier, PG, Blamire, AM. Three-year quantitative magnetic resonance imaging and phosphorus magnetic resonance spectroscopy study in lower limb muscle in dysferlinopathy. Journal of Cachexia Sarcopenia and Muscle. 2022; 13(3)DOI:10.1002/jcsm.12987. PMID:35373496. IF:8.900(Q1/1D).

01/06/2022 An Integrative Analysis of DNA Methylation Pattern in Myotonic Dystrophy Type 1 Samples Reveals a Distinct DNA Methylation Profile between Tissues and a Novel Muscle-Associated Epigenetic Dysregulation

Koehorst, E, Odria, R, Capo, J, Nunez-Manchon, J, Arbex, A, Almendrote, M, Linares-Pardo, I, Natera-de Benito, D, Saez, V, Nascimento, A, Ortez, C, Rubio, MA, Diaz-Manera, J, Alonso-Perez, J, Lucente, G, Rodriguez-Palmero, A, Ramos-Fransi, A, Martinez-Pineiro, A, Nogales-Gadea, G, Suelves, M. An Integrative Analysis of DNA Methylation Pattern in Myotonic Dystrophy Type 1 Samples Reveals a Distinct DNA Methylation Profile between Tissues and a Novel Muscle-Associated Epigenetic Dysregulation. Biomedicines. 2022; 10(6)DOI:10.3390/biomedicines10061372. PMID:35740394. IF:4.700(Q1/3D).

01/05/2022 Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder

Lopez-Soley, E, Meca-Lallana, JE, Llufriu, S, Blanco, Y, Gomez-Ballesteros, R, Maurino, J, Perez-Miralles, F, Forero, L, Calles, C, Martinez-Gines, ML, Gonzalez-Suarez, I, Boyero, S, Romero-Pinel, L, Sempere, AP, Meca-Lallana, V, Querol, L, Costa-Frossard, L, Sepulveda, M, Solana, E. Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder. Journal of Personalized Medicine. 2022; 12(5)DOI:10.3390/jpm12050743. PMID:35629165. IF:3.508(Q2/4D).

05/04/2022 Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis

Guasp, M, Martin-Aguilar, L, Sabater, L, Bioque, M, Armangue, T, Martinez-Hernandez, E, Landa, J, Maudes, E, Borras, R, Munoz-Lopetegi, A, Saiz, A, Castro-Fornieles, J, Graus, F, Parellada, E, Querol, L, Dalmau, J. Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis. NEUROLOGY. 2022; 98(14)DOI:10.1212/WNL.0000000000200021. PMID:35145006. IF:9.900(Q1/1D).

01/12/2024 A nationwide Guillain-Barré syndrome epidemiological study in Spain during the COVID-19 years

Blanco-Ruiz, M, Martín-Aguilar, L, Caballero-Avila, M, Lleixà, C, Pascual-Goñi, E, Collet-Vidiella, R, Tejada-Illa, C, Turon-Sans, J, Carbayo, A, Llansó, L, Cortés, E, Pascasio, LA, Querol, L. A nationwide Guillain-Barré syndrome epidemiological study in Spain during the COVID-19 years. EUROPEAN JOURNAL OF NEUROLOGY. 2024; 31(12)DOI:10.1111/ene.16439. PMID:39132887. IF:3.900(Q1/3D).

13/11/2024 Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease

Kishnani, PS, Byrne, BJ, Claeys, KG, Díaz-Manera, J, Dimachkie, MM, Kushlaf, H, Mozaffar, T, Roberts, M, Schoser, B, Hummel, N, Kopiec, A, Holdbrook, F, Shohet, S, Toscano, A. Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease. Journal Of Patient-Reported Outcomes. 2024; 8(1)DOI:10.1186/s41687-024-00805-w. PMID:39535661. IF:(Q/D).

01/11/2024 Modified radioimmunoassay versus ELISA to quantify anti-acetylcholine receptor antibodies in a mouse model of myasthenia gravis

Mariscal, A, Martínez, C, Goethals, L, Cortés-Vicente, E, Moltó, E, Juárez, C, Barneda-Zahonero, B, Querol, L, Le Panse, R, Gallardo, E. Modified radioimmunoassay versus ELISA to quantify anti-acetylcholine receptor antibodies in a mouse model of myasthenia gravis. JOURNAL OF IMMUNOLOGICAL METHODS. 2024; 534DOI:10.1016/j.jim.2024.113748. PMID:39241980. IF:1.600(Q4/9D).

25/10/2024 Inflammatory Neuropathy Consortium base (INCbase): a protocol of a global prospective observational cohort study for the development of a prediction model for treatment response in chronic inflammatory demyelinating polyneuropathy

Michael, MR, Wieske, L, Allen, JA, Lunn, MP, Doppler, K, Tan, CY, Koike, H, Markvardsen, LK, Kapoor, M, Hsieh, ST, Nobile-Orazio, E, Jacobs, BC, Rajabally, YA, Basta, I, Ripellino, P, Querol, L, Eftimov, F. Inflammatory Neuropathy Consortium base (INCbase): a protocol of a global prospective observational cohort study for the development of a prediction model for treatment response in chronic inflammatory demyelinating polyneuropathy. BMC Neurology. 2024; 24(1)DOI:10.1186/s12883-024-03903-w. PMID:39455929. IF:2.200(Q3/6D).

17/10/2024 Decoding the muscle transcriptome of patients with late-onset Pompe disease reveals markers of disease progression

Monceau, A, Nath, RG, Suárez-Calvet, X, Musumeci, O, Toscano, A, Kierdaszuk, B, Kostera-Pruszczyk, A, Domínguez-González, C, Hernández-Lain, A, Paradas, C, Rivas, E, Papadimas, G, Papadopoulos, C, Chrysanthou-Piterou, M, Gallardo, E, Olivé, M, Lilleker, J, Roberts, ME, Marchese, D, Lunazzi, G, Heyn, H, Fernández-Simón, E, Villalobos, E, Clark, J, Katsikis, P, Collins, C, Mehra, P, Laidler, Z, Vincent, A, Tasca, G, Marini-Bettolo, C, Guglieri, M, Straub, V, Raben, N, Díaz-Manera, J. Decoding the muscle transcriptome of patients with late-onset Pompe disease reveals markers of disease progression. BRAIN. 2024; DOI:10.1093/brain/awae249. PMID:39045638. IF:11.700(Q1/1D).

01/10/2024 Does serum neurofilament light chain measurement influence therapeutic decisions in multiple sclerosis?

Saposnik, G, Monreal, E, Medrano, N, García-Domínguez, JM, Querol, L, Meca-Lallana, JE, Landete, L, Salas, E, Meca-Lallana, V, García-Arcelay, E, Agüera-Morales, E, Martínez-Yélamos, S, Gómez-Ballesteros, R, Maurino, J, Villar, LM, Caminero, AB. Does serum neurofilament light chain measurement influence therapeutic decisions in multiple sclerosis?. Multiple Sclerosis and Related Disorders. 2024; 90DOI:10.1016/j.msard.2024.105838. PMID:39216454. IF:2.900(Q2/4D).

01/10/2024 Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE) : a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial

Allen, JA, Lin, J, Basta, I, Dysgaard, T, Eggers, C, Guptill, J, Gwathmey, KG, Hewamadduma, C, Hofman, E, Hussain, YM, Kuwabara, S, Le Masson, G, Leypoldt, F, Chang, T, Lipowska, M, Lowe, M, Lauria, G, Querol, L, Simu, MA, Suresh, N, Tse, A, Ulrichts, P, Van Hoorick, B, Yamasaki, R, Lewis, RA, van Doorn, PA. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE) : a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. LANCET NEUROLOGY. 2024; 23(10)DOI:10.1016/S1474-4422(24)00309-0. PMID:39304241. IF:45.500(Q1/1D).

01/10/2024 MRI for the diagnosis of limb girdle muscular dystrophies

Bolano-Díaz, C, Verdú-Díaz, J, Díaz-Manera, J. MRI for the diagnosis of limb girdle muscular dystrophies. CURRENT OPINION IN NEUROLOGY. 2024; 37(5)DOI:10.1097/WCO.0000000000001305. PMID:39132784. IF:4.400(Q1/2D).

01/09/2024 Absence of Pathogenic Mutations and Strong Association With HLA-DRB1*11:01 in Statin-Naïve Early-Onset Anti-HMGCR Necrotizing Myopathy

Llansó, L, Segarra-Casas, A, Domínguez-González, C, Malfatti, E, Kapetanovic, S, Rodríguez-Santiago, B, de la Calle, O, Blanco, R, Dobrescu, A, Nascimento-Osorio, A, Paipa, A, Hernandez-Lain, A, Jou, C, Mariscal, A, González-Mera, L, Arteche, A, Lleixa, C, Caballero-Avila, M, Carbayo, A, Vesperinas, A, Querol, L, Gallardo, E, Olivé, M. Absence of Pathogenic Mutations and Strong Association With HLA-DRB1*11:01 in Statin-Naïve Early-Onset Anti-HMGCR Necrotizing Myopathy. Neurology-Neuroimmunology & Neuroinflammation. 2024; 11(5)DOI:10.1212/NXI.0000000000200285. PMID:39106428. IF:7.500(Q1/1D).

01/08/2024 The impact of diagnosis delay on European patients with generalised myasthenia gravis

Cortes-Vicente, E, Borsi, AJ, Gary, C, Noel, WGJ, Lee, JMS, Karmous, W, Zhang, QY, Gandhi, KH, Batista, AE, Decourcy, JJ, Barlow, SG, Birija, SL, Gibson, GA. The impact of diagnosis delay on European patients with generalised myasthenia gravis. Annals of Clinical and Translational Neurology. 2024; 11(9)DOI:10.1002/acn3.52122. PMID:39090840. IF:3.900(Q1/3D).

01/08/2024 ANTI-HNK-1 IGM AND SNFL LEVELS ARE POTENTIAL BIOMARKERS FOR MONITORING DISEASE ACTIVITY IN ANTI-MAG NEUROPATHY

Pascual-Goñi, E, Martín-Aguilar, L, Lleixà, C, Mariscal, A, Tejada-Illa, C, Caballero-Avila, M, Martinez-Hernandez, E, Serfim, A, Moga, E, Rojas-García, R, López-Pardo, J, Novelli, S, Gallardo, E, Sabater, L, Querol, L. ANTI-HNK-1 IGM AND SNFL LEVELS ARE POTENTIAL BIOMARKERS FOR MONITORING DISEASE ACTIVITY IN ANTI-MAG NEUROPATHY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2024 ANTI-CASPR1 AUTOIMMUNE NODOPATHY AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION

Collet-Vidiella, R, Mederer-Fernandez, T, Caballero-Avila, M, Tejada-Illa, C, Pascual-Goñi, E, Martín-Aguilar, L, Lleixà, C, Querol, L. ANTI-CASPR1 AUTOIMMUNE NODOPATHY AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2024 ANTI-CASPR1 ANTIBODIES ARE ASSOCIATED WITH HLA-DRB1*03:01 ALLELES

Lleixà, C, Martínez-Martínez, L, Pascual-Goñi, E, Martín-Aguilar, L, Caballero-Avila, M, Collet, R, Illa, CT, Gallardo, E, Boera-Carnicero, G, Calahorro, V, Martín, OD, Callegari, I, Cortese, A, Delmont, E, Devaux, J, Giannotta, C, Nobie-Orazio, E, Höftberger, R, Herdewyn, S, Carvajal, A, Torné, L, Jericó-Pascual, I, Querol, L. ANTI-CASPR1 ANTIBODIES ARE ASSOCIATED WITH HLA-DRB1*03:01 ALLELES. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2024 CHARACTERISTICS OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY SUBTYPES: RESULTS FROM A MULTINATIONAL, REAL-WORLD SURVEY

Querol, L, Borsi, A, Gary, C, Noel, W, Karmous, W, DeCourcy, J, Wright, J, Taylor, Y, Iqbal, H, Rinaldi, S. CHARACTERISTICS OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY SUBTYPES: RESULTS FROM A MULTINATIONAL, REAL-WORLD SURVEY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2024 LONGITUDINAL GAIT ASSESSMENT USING A WEARABLE SYSTEM DETECTS CLINICALLY SIGNIFICANT CHANGES IN PATIENTS WITH PERIPHERAL NEUROPATHIES

Illa, CT, Pegueroles, J, Claramunt-Molet, M, Pi-Cervera, A, Heras-Delgado, A, Gascón-Fontal, J, Idelsohn-Zielonka, S, Vidal, N, Martín-Aguilar, L, Caballero-Avila, M, Lleixà, C, Llansó, L, Rojas-García, R, Querol, L, Pascual-Goñi, E. LONGITUDINAL GAIT ASSESSMENT USING A WEARABLE SYSTEM DETECTS CLINICALLY SIGNIFICANT CHANGES IN PATIENTS WITH PERIPHERAL NEUROPATHIES. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2024 EMPASIPRUBART (ARGX-117) IN MULTIFOCAL MOTOR NEUROPATHY: INITIAL SAFETY AND EFFICACY DATA OF THE PHASE 2 ARDA STUDY

van der Pol, WL, Peric, S, Querol, L, Hussain, Y, Cadour, S, Van de Walle, I, Persson, E, Van Hoomissen, I, Mashchenko, O, Vujcic, M, Van de Steen, O, Allen, JA. EMPASIPRUBART (ARGX-117) IN MULTIFOCAL MOTOR NEUROPATHY: INITIAL SAFETY AND EFFICACY DATA OF THE PHASE 2 ARDA STUDY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2024 SERUM PROTEOME IN GUILLAIN-BARRE SYNDROME USING AN APTAMER-BASED PROTEOMICS PLATFORM

Martín-Aguilar, L, Collet, R, Lleixà, C, Caballero-Avila, M, Tejada-Illa, C, Pascual-Goñi, E, Sedano-Tous, MJ, Casasnovas, C, Gutiérrez-Gutiérrez, G, Pardo-Fernández, J, Rojas, R, Turón, J, Gallardo, E, Cortés-Vicente, E, Llansó, L, García, JM, Farrés, J, Querol, L. SERUM PROTEOME IN GUILLAIN-BARRE SYNDROME USING AN APTAMER-BASED PROTEOMICS PLATFORM. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2024 CLINICAL AND IMMUNOLOGICAL RELAPSES ARE INFREQUENT IN PATIENTS WITH ANTI-CNTN1 AUTOIMMUNE NODOPATHY

Caballero-Avila, M, Martín-Aguilar, L, Pascual-Goñi, E, Tejada-Illa, C, Collet, R, Rojas-García, R, Gallardo, E, Martínez-Martínez, L, Doneddu, P, Nobile-Orazio, E, de Winter, J, Alonso-Jimenez, A, del Real, MA, Armangué, T, Delmont, E, Xuclà-Ferrarons, T, Roche, JC, Jauregui, A, González, A, Ortiz, N, Liong, HF, de Rivera, FJR, Sparasci, D, Ripellino, P, Pérez-Pérez, H, Guerrero-Sola, A, Vegezzi, E, Baars, A, Jacobs, B, Wieske, L, Eftimov, F, Lleixà, C, Querol, L. CLINICAL AND IMMUNOLOGICAL RELAPSES ARE INFREQUENT IN PATIENTS WITH ANTI-CNTN1 AUTOIMMUNE NODOPATHY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2024 PHASE 3 TRIAL DESIGNS EVALUATING RILIPRUBART, A C1S-COMPLEMENT INHIBITOR, IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

Lewis, RA, Allen, J, Merkies, ISJ, van Doorn, PA, Sommer, C, Wallstroem, E, Luo, XD, Alonso-Alonso, M, Atassi, N, Querol, L. PHASE 3 TRIAL DESIGNS EVALUATING RILIPRUBART, A C1S-COMPLEMENT INHIBITOR, IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2024 PHASE 2 EFFICACY AND SAFETY OF RILIPRUBART, A C1S-COMPLEMENT INHIBITOR, IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

Querol, L, Lewis, RA, Hartung, HP, Van Doorn, PA, Wallstroem, E, Auwarter, K, Luo, XD, Alonso-Alonso, M, Atassi, N, Hughes, RAC. PHASE 2 EFFICACY AND SAFETY OF RILIPRUBART, A C1S-COMPLEMENT INHIBITOR, IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2024 PHASE 2 TRIAL OF RILIPRUBART IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: QUALITY-OF-LIFE AND FATIGUE

Van Doorn, PA, Querol, L, Hartung, HP, Hughes, RAC, Orsini, M, Hakimi-Hawken, N, Minor, C, Msihid, J, Alonso-Alonso, M, Atassi, N, Lewis, R. PHASE 2 TRIAL OF RILIPRUBART IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: QUALITY-OF-LIFE AND FATIGUE. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2024 PHASE 2 TRIAL OF RILIPRUBART IN CIDP: EFFECT ON COMPLEMENT BIOMARKERS AND NEUROFILAMENT LIGHT CHAIN

Querol, L, Lewis, RA, Van Doorn, PA, Hughes, RAC, Storek, M, Rajagopal, V, Chow, T, Luo, XD, Alonso-Alonso, M, Atassi, N, Hartung, HP. PHASE 2 TRIAL OF RILIPRUBART IN CIDP: EFFECT ON COMPLEMENT BIOMARKERS AND NEUROFILAMENT LIGHT CHAIN. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2024 CLINICAL AND GENETIC SPECTRUM OF PATIENTS WITH BAG3-RELATED NEUROMUSCULAR DISORDERS IN EUROPE

Fernandez-Eulate, G, Gitiaux, C, Thiele, S, Jungbluth, H, Audic, F, Potulska-Chromik, A, Marini-Bettolo, C, Davion, JB, de la Tassa, GM, Olivé, M, de la Hoz, CPDF, Isapof, A, Töpf, A, Walter, M, Angelini, C, Claeys, K, Kostera-Pruszczyk, A, Attarian, S, Straub, V, Domínguez-González, C, Vissing, J, Metay, C, Khraiche, D, Wahbi, K, Stojkovic, T. CLINICAL AND GENETIC SPECTRUM OF PATIENTS WITH BAG3-RELATED NEUROMUSCULAR DISORDERS IN EUROPE. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2024 TREATMENT RESPONSE AND REFRACTORINESS IN PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (INCBASE)

Michael, M, Wieske, L, Allen, J, Lunn, M, Doppler, K, Tan, CY, Koike, H, Markvardsen, L, Kapoor, M, Hsieh, ST, Nobie-Orazio, E, Jacobs, B, Rajabally, Y, Basta, I, Ripellino, P, Querol, L, Eftimov, F. TREATMENT RESPONSE AND REFRACTORINESS IN PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (INCBASE). JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2024 RASCH-BUILT ATAXIA RATING SALE FOR IGM-ASSOCIATED POLYNEUROPATHY WITH AND WITHOUT ANTI-MAG ANTIBODIES (IGM-PNP RB-ARS)

Hamadeh, T, van de Mortel, J, Van Doormaal, P, Cornblath, D, Vrancken, AFJE, Faber, C, Goedee, S, Minnema, M, Thomas, S, Khoshnoodi, M, Lunn, M, Keddie, S, Carr, A, D'Sa, S, Mair, D, Querol, L, Pascual-Goñi, E, Illa, CT, Harbo, T, Orazio, EN, Cutellè, C, Bianco, M, Svahn, J, Merle, H, Karlin, L, Echaniz-Laguna, A, Cauquil, C, Labeyrie, C, Peric, S, Basta, I, Palibrk, A, Stinoc, A, Briani, C, Salvalaggio, A, Marasca, M, Van den Bergh, P, Dubuisson, N, Marques, W Jr, Nascimento, O, Elsheikh, B, Doughty, C, Attarian, S, Delmont, E, Rausch, HW, Schirmer, L, Notermans, NC, Merkies, ISJ. RASCH-BUILT ATAXIA RATING SALE FOR IGM-ASSOCIATED POLYNEUROPATHY WITH AND WITHOUT ANTI-MAG ANTIBODIES (IGM-PNP RB-ARS). JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2024 DISSECTING THE GENETIC ARCHITECTURE OF CIDP. STUDY PROTOCOL FOR AN INTERNATIONAL COLLABORATIVE GENOME-WIDE ASSOCIATION STUDY

Doneddu, P, Asselta, R, Manganelli, F, Cocito, D, Inghilleri, M, Ricciardi, D, Cavaletti, G, Di Stefano, V, Filosto, M, Carta, A, Vegezzi, E, Matà, S, Habetswallner, F, Farotti, L, Luigetti, M, Ruiu, E, Mataluni, G, Falzone, Y, Carpo, M, Leonardi, L, Gentile, L, Ripellino, P, Peric, S, Basta, I, Querol, L, Jacobs, B, Eftimov, F, Orazio, EN. DISSECTING THE GENETIC ARCHITECTURE OF CIDP. STUDY PROTOCOL FOR AN INTERNATIONAL COLLABORATIVE GENOME-WIDE ASSOCIATION STUDY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2024 EFFICACY AND SAFETY OF SUBCUTANEOUS (SC) EFGARTIGIMOD PH20 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: ADHERE/ADHERE plus TRIALS

Allen, J, Van Doorn, PA, Basta, I, Dysgaard, T, Eggers, C, Guptill, J, Gwathmey, K, Hewamadduma, C, Hofman, E, Hussain, Y, Kuwabara, S, Le Masson, G, Leypoldt, F, Lin, J, Lipowska, M, Lowe, M, Pinter, GL, Querol, L, Simu, MA, Chang, T, Tse, A, Ulrichts, P, Van Hoorick, B, Yamasaki, R, Lewis, RA. EFFICACY AND SAFETY OF SUBCUTANEOUS (SC) EFGARTIGIMOD PH20 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: ADHERE/ADHERE plus TRIALS. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

01/07/2024 Inter-laboratory comparison of routine autoantibody detection methods for autoimmune neuropathies and myasthenia gravis

Martínez-Martínez, L, Lacruz, AC, Querol, L, Cortés-Vicente, E, Pascual, E, Rojas-García, R, Reyes-Leiva, D, Alvaro, Y, Moltó, E, Ortiz, E, Gallardo, E, Juárez, C, Mariscal, A. Inter-laboratory comparison of routine autoantibody detection methods for autoimmune neuropathies and myasthenia gravis. JOURNAL OF NEUROLOGY. 2024; 271(7)DOI:10.1007/s00415-024-12317-0. PMID:38578496. IF:4.600(Q1/2D).

11/06/2024 Editorial: New perspectives in the treatment of myasthenia gravis

Cortés-Vicente, E, Schreiner, B, Saccà, F, Narayanaswami, P. Editorial: New perspectives in the treatment of myasthenia gravis. Frontiers in Neurology. 2024; 15DOI:10.3389/fneur.2024.1418631. PMID:38919972. IF:2.800(Q2/5D).

01/06/2024 Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy

Saccà, F, Salort-Campana, E, Jacob, S, Cortés-Vicente, E, Schneider-Gold, C. Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy. EUROPEAN JOURNAL OF NEUROLOGY. 2024; 31(6)DOI:10.1111/ene.16180. PMID:38117543. IF:3.900(Q1/3D).

01/05/2024 Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial

Tawil, R, Wagner, KR, Hamel, J, Leung, DG, Statland, JM, Wang, LH, Genge, A, Sacconi, S, Lochmüller, H, Reyes-Leiva, D, Diaz-Manera, J, Alonso-Perez, J, Muelas, N, Vilchez, JJ, Pestronk, A, Gibson, S, Goyal, NA, Hayward, LJ, Johnson, N, LoRusso, S, Freimer, M, Shieh, PB, Subramony, SH, van Engelen, B, Kools, J, Leinhard, OD, Widholm, P, Morabito, C, Moxham, CM, Cadavid, D, Mellion, ML, Odueyungbo, A, Tracewell, WG, Accorsi, A, Ronco, L, Gould, RJ, Shoskes, J, Rojas, LA, Jiang, JG. Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial. LANCET NEUROLOGY. 2024; 23(5)DOI:10.1016/S1474-4422(24)00073-5. PMID:38631764. IF:45.500(Q1/1D).

09/02/2024 Imaging mass cytometry analysis of Becker muscular dystrophy muscle samples reveals different stages of muscle degeneration

Piñol-Jurado, P, Verdú-Díaz, J, Fernández-Simón, E, Domínguez-González, C, Hernández-Lain, A, Lawless, C, Vincent, A, González-Chamorro, A, Villalobos, E, Monceau, A, Laidler, Z, Mehra, P, Clark, J, Filby, A, Mcdonald, D, Rushton, P, Bowey, A, Perez, JA, Tasca, G, Marini-Bettolo, C, Guglieri, M, Straub, V, Suarez-Calvet, X, Diaz-Manera, J. Imaging mass cytometry analysis of Becker muscular dystrophy muscle samples reveals different stages of muscle degeneration. Scientific Reports. 2024; 14(1)DOI:10.1038/s41598-024-51906-x. PMID:38336890. IF:3.900(Q1/2D).

09/02/2024 Excellent response to anti-CD38 therapy with daratumumab in a patient with severe refractory CANOMAD

Pascual-Goñi, E, Collet, R, Tejada-Illa, C, Martín-Aguilar, L, Caballero-Avila, M, Lleixà, C, Novelli, S, López-Pardo, J, Sanfeliu, AE, Mariscal, A, Gargallo, YA, Martínez-Hernández, E, Cocho, D, Querol, L. Excellent response to anti-CD38 therapy with daratumumab in a patient with severe refractory CANOMAD. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2024; 95(7)DOI:10.1136/jnnp-2023-332443. PMID:38341197. IF:7.500(Q1/1D).

01/01/2024 Magnetic resonance imaging-based criteria to differentiate dysferlinopathy from other genetic muscle diseases

Bolano-Diaz, C, Verdú-Díaz, J, Gonzalez-Chamorro, A, Fitzsimmons, S, Veeranki, G, Straub, V, Diaz-Manera, J. Magnetic resonance imaging-based criteria to differentiate dysferlinopathy from other genetic muscle diseases. NEUROMUSCULAR DISORDERS. 2024; 34DOI:10.1016/j.nmd.2023.11.004. PMID:38007344. IF:2.800(Q2/5D).

01/01/2024 Correction to: Analysis of muscle magnetic resonance imaging of a large cohort of patient with VCP-mediated disease reveals characteristic features useful for diagnosis (Journal of Neurology, (2023), 270, 12, (5849-5865), 10.1007/s00415-023-11862-4)

Esteller D., Schiava M., Verdú-Díaz J., Villar-Quiles R.-N., Dibowski B., Venturelli N., Laforet P., Alonso-Pérez J., Olive M., Domínguez-González C., Paradas C., Vélez B., Kostera-Pruszczyk A., Kierdaszuk B., Rodolico C., Claeys K., Pál E., Malfatti E., Souvannanorath S., Alonso-Jiménez A., de Ridder W., De Smet E., Papadimas G., Papadopoulos C., Xirou S., Luo S., Muelas N., Vilchez J.J., Ramos-Fransi A., Monforte M., Tasca G., Udd B., Palmio J., Sri S., Krause S., Schoser B., Fernández-Torrón R., López de Munain A., Pegoraro E., Farrugia M.E., Vorgerd M., Manousakis G., Chanson J.B., Nadaj-Pakleza A., Cetin H., Badrising U., Warman-Chardon J., Bevilacqua J., Earle N., Campero M., Díaz J., Ikenaga C., Lloyd T.E., Nishino I., Nishimori Y., Saito Y., Oya Y., Takahashi Y., Nishikawa A., Sasaki R., Marini-Bettolo C., Guglieri M., Straub V., Stojkovic T., Carlier R.Y., Díaz-Manera J.. Correction to: Analysis of muscle magnetic resonance imaging of a large cohort of patient with VCP-mediated disease reveals characteristic features useful for diagnosis (Journal of Neurology, (2023), 270, 12, (5849-5865), 10.1007/s00415-023-11862-4). JOURNAL OF NEUROLOGY. 2024; 271(4)DOI:10.1007/s00415-023-12178-z. PMID:38349561. IF:4.600(Q1/2D).

01/12/2023 Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study

Fonseca, E, Cabrera-Maqueda, JM, Ruiz-Garcia, R, Naranjo, L, Diaz-Pedroche, C, Velasco, R, Macias-Gomez, A, Milisenda, JC, Munoz-Farjas, E, Pascual-Goni, E, Perez-Larraya, JG, Saiz, A, Dalmau, J, Blanco, Y, Graus, F, Martinez-Hernandez, E. Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study. LANCET NEUROLOGY. 2023; 22(12)DOI:10.1016/S1474-4422(23)00335-6. PMID:37977714. IF:46.600(Q1/1D).

01/12/2023 Distal myopathy due to digenic inheritance of TIA1 and SQSTM1 variants in two unrelated Spanish patients

Bermejo-Guerrero, L, Fernández-de la Hoz, CPD, González-Quereda, L, Segarra-Casas, A, Nedkova, V, Gallano, P, Martín-Jiménez, P, Hernández-Laín, A, Olivé, M, Arteche-López, A, Domínguez-González, C. Distal myopathy due to digenic inheritance of TIA1 and SQSTM1 variants in two unrelated Spanish patients. NEUROMUSCULAR DISORDERS. 2023; 33(12)DOI:10.1016/j.nmd.2023.10.016. PMID:38016875. IF:2.700(Q2/4D).

27/11/2023 Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian database (vol 43, pg 3939, 2022)

Liberatore, G, De Lorenzo, A, Giannotta, C, Manganelli, F, Filosto, M, Cosentino, G, Cocito, D, Briani, C, Cortese, A, Fazio, R, Lauria, G, Clerici, AM, Rosso, T, Marfia, GA, Antonini, G, Cavaletti, G, Carpo, M, Doneddu, PE, Spina, E, Piccinelli, SC, Peci, E, Querol, L, Nobile-Orazio, E. Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian database (vol 43, pg 3939, 2022). NEUROLOGICAL SCIENCES. 2023; DOI:10.1007/s10072-023-07184-y. PMID:38008812. IF:2.700(Q2/4D).

25/10/2023 Clinical relevance of distinguishing autoimmune nodopathies from CIDP: longitudinal assessment in a large cohort

Broers, MC, Wieske, L, Erdag, E, Gürlek, C, Bunschoten, C, van Doorn, PA, Eftimov, F, Kuitwaard, K, de Vries, JM, de Wit, MCY, Nagtzaam, MMP, Franken, SC, Zhu, LIS, Paunovic, M, de Wit, M, Schreurs, MWJ, Lleixà, C, Martín-Aguilar, L, Pascual-Goñi, E, Querol, L, Jacobs, BC, Huizinga, R, Titulaer, MJ. Clinical relevance of distinguishing autoimmune nodopathies from CIDP: longitudinal assessment in a large cohort. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2023; 95(1)DOI:10.1136/jnnp-2023-331378. PMID:37879898. IF:8.800(Q1/1D).

20/10/2023 Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study

Meca-Lallana J.E., Prieto González J.M., Caminero Rodríguez A.B., Olascoaga Urtaza J., Alonso A.M., Durán Ferreras E., Espinosa R., Dotor J., Romera M., Ares Luque A., Pérez Ruiz D., Calles C., Hernández M.A., Hervás García M., Mendoza Rodríguez A., Berdei Montero Y., Téllez N., Herrera Varó N., Sotoca J., Presas-Rodríguez S., Querol Gutierrez L.A., Hervás Pujol M., Batlle Nadal J., Martín Ozaeta G., Gubieras Lillo L., Martínez Yélamos S., Ramió-Torrentà L., Mallada Frechin J., Belenguer Benavides A., Gascón-Giménez F., Casanova B., Landete Pascual L., Berenguer L., Navarro L., Gómez Gutierrez M., Durán C., Rodríguez Regal A., Álvarez E., García-Estévez D.A., López Real A.M., Llaneza González M.A., Marzo Sola M.E., Sánchez-Menoyo J.L., Oterino A., Villaverde González R., Castillo-Triviño T., Álvarez de Arcaya A., Llarena C.. Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study. Neurology and Therapy. 2023; 12(6)DOI:10.1007/s40120-023-00557-7. PMID:37861931. IF:4.000(Q1/2D).

10/10/2023 European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome

van Doorn P.A., Van den Bergh P.Y.K., Hadden R.D.M., Avau B., Vankrunkelsven P., Attarian S., Blomkwist-Markens P.H., Cornblath D.R., Goedee H.S., Harbo T., Jacobs B.C., Kusunoki S., Lehmann H.C., Lewis R.A., Lunn M.P., Nobile-Orazio E., Querol L., Rajabally Y.A., Umapathi T., Topaloglu H.A., Willison H.J.. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome. EUROPEAN JOURNAL OF NEUROLOGY. 2023; 30(12)DOI:10.1111/ene.16073. PMID:37814552. IF:4.500(Q1/2D).

10/10/2023 European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome

van Doorn P.A., Van den Bergh P.Y.K., Hadden R.D.M., Avau B., Vankrunkelsven P., Attarian S., Blomkwist-Markens P.H., Cornblath D.R., Goedee H.S., Harbo T., Jacobs B.C., Kusunoki S., Lehmann H.C., Lewis R.A., Lunn M.P., Nobile-Orazio E., Querol L., Rajabally Y.A., Umapathi T., Topaloglu H.A., Willison H.J.. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2023; 28(4)DOI:10.1111/jns.12594. PMID:37814551. IF:4.000(Q1/2D).

21/08/2023 Analysis of muscle magnetic resonance imaging of a large cohort of patient with VCP-mediated disease reveals characteristic features useful for diagnosis

Esteller D., Schiava M., Villar-Quiles, RN, Dibowski B., Venturelli N., Laforet P., Alonso-Pérez J., Olive M., Domínguez-González C., Paradas C., Vélez B., Kostera-Pruszczyk A., Kierdaszuk B., Rodolico C., Claeys K., Pál E., Malfatti E., Souvannanorath S., Alonso-Jiménez A., de Ridder W., De Smet E., Papadimas G., Papadopoulos C., Xirou S., Luo S., Muelas N., Vilchez J.J., Ramos-Fransi A., Monforte M., Tasca G., Udd B., Palmio J., Sri S., Krause S., Schoser, B, Fernández-Torrón R., de Munain, AL, Pegoraro E., Farrugia M.E., Vorgerd M., Manousakis G., Chanson J.B., Nadaj-Pakleza A., Cetin H., Badrising U., Warman-Chardon J., Bevilacqua J., Earle N., Campero M., Díaz J., Ikenaga C., Lloyd T.E., Nishino I., Nishimori Y., Saito Y., Oya Y., Takahashi Y., Nishikawa A., Sasaki R., Marini-Bettolo C., Guglieri M., Straub V., Stojkovic T., Carlier R.Y., Díaz-Manera J.. Analysis of muscle magnetic resonance imaging of a large cohort of patient with VCP-mediated disease reveals characteristic features useful for diagnosis. JOURNAL OF NEUROLOGY. 2023; 270(12)DOI:10.1007/s00415-023-11862-4. PMID:37603075. IF:4.800(Q1/2D).